Preface........................................................................................................................................... i
Public Health Nursing Protocol Agreement.................................................................................. ii
Table of Contents......................................................................................................................... iii

SECTION I: EMERGENCY MANAGEMENT

ACUTE ASTHMA ATTACK ........................................................................................................... 1.010
ACUTE POISONING ..................................................................................................................... 1.020
ANAPHYLAXIS ............................................................................................................................. 1.030

Emergency Drug Chart

ANIMAL BITES ......................................................................................................................... 1.040
BURN - FIRST DEGREE ............................................................................................................. 1.050
CARDIAC EMERGENCIES ......................................................................................................... 1.060
EMERGENCY CHILDBIRTH ....................................................................................................... 1.070

Apgar Scoring System

HEMORRHAGE/HEMORRHAGIC SHOCK .............................................................................. 1.080
INSECT (NON SPIDER) BITES ................................................................................................. 1.090
LACERATION ............................................................................................................................... 1.100
PUNCTURE WOUND ............................................................................................................... 1.110
RESPIRATORY EMERGENCY .................................................................................................... 1.120
SEIZURES ..................................................................................................................................... 1.130
SHOCK .......................................................................................................................................... 1.140
SUSPECTED OPIOID OVERDOSE ........................................................................................... 1.145
SYNCOPE/VASOVAGAL REACTION/COMMON FAINT ............................................................. 1.150
TICK BITE .................................................................................................................................... 1.160
VACCINATION CLINIC, COMMUNITY LOCATED .................................................................. 1.170

SECTION II: FAMILY PLANNING

ALL METHODS, QUICK START ................................................................................................. 2.010
BASIC INFERTILITY SERVICES ............................................................................................... 2.011
CERVICAL CANCER SCREENING ........................................................................................... 2.020
COMBINED HORMONAL CONTRACEPTION ........................................................................... 2.030
CONDOMS, SPONGE, AND SPERMICIDAL AGENTS ................................................................ 2.040
DIAPHRAGM ............................................................................................................................... 2.060
DYSMENORRHEA ....................................................................................................................... 2.070
EMERGENCY CONTRACEPTIVE PILLS (ECPS) .................................................................. 2.080
FERTILITY AWARENESS-BASED METHODS (FAM) ............................................................... 2.090
INTRAUTERINE CONTRACEPTIVE (IUC) ................................................................................ 2.100
PRECONCEPTION HEALTH SERVICES ...................................................................................... 2.105
PREGNANCY TEST ................................................................................................................... 2.110
PROGESTIN-ONLY IMPLANT(S) ............................................................................................... 2.120
PROGESTIN-ONLY INJECTABLE CONTRACEPTION ............................................................... 2.130
PROGESTIN-ONLY PILLS (MINIPILL) .................................................................................... 2.140
STERILIZATION ......................................................................................................................... 2.150
# Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use

**SECTION III: GENERAL**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACNE</td>
<td>3.010</td>
</tr>
<tr>
<td>ACUTE UPPER RESPIRATORY INFECTION (COMMON COLD)</td>
<td>3.010</td>
</tr>
<tr>
<td>ANEMIA, IRON DEFICIENCY</td>
<td>3.020</td>
</tr>
<tr>
<td>ASCARIASIS (ROUNDWORMS)</td>
<td>3.030</td>
</tr>
<tr>
<td>BLOOD PRESSURE, ELEVATED, ADULT</td>
<td>3.040</td>
</tr>
<tr>
<td>BLOOD PRESSURE, ELEVATED, CHILD</td>
<td>3.050</td>
</tr>
<tr>
<td>CERUMEN, IMPACTED (EAR WAX)</td>
<td>3.060</td>
</tr>
<tr>
<td>CHIGGERS, (DEMATOPHILIS PENTRANS)</td>
<td>3.070</td>
</tr>
<tr>
<td>Childhood Anemia RESCINDED FEB 2013</td>
<td>3.080</td>
</tr>
<tr>
<td>CHOLESTEROL RISK ASSESSMENT</td>
<td>3.090</td>
</tr>
<tr>
<td>CONSTIPATION, ACUTE, CHILD</td>
<td>3.100</td>
</tr>
<tr>
<td>CONSTIPATION, ADULT</td>
<td>3.110</td>
</tr>
<tr>
<td>DIAPER DERMATITIS (DIAPER RASH)</td>
<td>3.120</td>
</tr>
<tr>
<td>DIARRHEA</td>
<td>3.130</td>
</tr>
<tr>
<td>DILATION FOR RETINAL IMAGING</td>
<td>3.135</td>
</tr>
<tr>
<td>ENTEROBIUS VERMICULARIS (PINWORMS)</td>
<td>3.140</td>
</tr>
<tr>
<td>Fever, Vaccine Associated RESCINDED MAY 2014</td>
<td>3.150</td>
</tr>
<tr>
<td>Refer to Appendices for Fever guidance</td>
<td></td>
</tr>
<tr>
<td>FLUORIDE DEFICIENCY</td>
<td>3.160</td>
</tr>
<tr>
<td>FLUORIDE VARNISH</td>
<td>3.170</td>
</tr>
<tr>
<td>FOLIC ACID PROPHYLACTIC THERAPY FOR WOMEN AGED 10-44</td>
<td>3.180</td>
</tr>
<tr>
<td>FOODBORNE OUTBREAK INVESTIGATION</td>
<td>3.190</td>
</tr>
<tr>
<td>HAEMOPHILUS INFLUENZA, INVASIVE TYPE B, CONTACT</td>
<td>3.200</td>
</tr>
<tr>
<td>HEPATITIS A, CASE OR PRESUMPTIVE</td>
<td>3.210</td>
</tr>
<tr>
<td>HEPATITIS A, POST EXPOSURE</td>
<td>3.220</td>
</tr>
<tr>
<td>HERPES SIMPLEX TYPE I (FEVER BLISTER)</td>
<td>3.230</td>
</tr>
<tr>
<td>HERPETIC STOMATITIS (GINGIVOSTOMATITIS)</td>
<td>3.240</td>
</tr>
<tr>
<td>HORDEOLUM (STY)</td>
<td>3.250</td>
</tr>
<tr>
<td>IMPETIGO/BULLOSUS IMPETIGO</td>
<td>3.260</td>
</tr>
<tr>
<td>Iron Deficiency Anemia age 18 and over RESCINDED FEB 2013</td>
<td>3.270</td>
</tr>
<tr>
<td>LEAD TOXICITY SCREENING</td>
<td>3.280</td>
</tr>
<tr>
<td>MENINGOCOCCAL DISEASE, CASE</td>
<td>3.290</td>
</tr>
<tr>
<td>MENINGOCOCCAL INVASIVE DISEASE, CONTACT</td>
<td>3.300</td>
</tr>
<tr>
<td>MILIARIA (PRICKLY HEAT, HEAT RASH)</td>
<td>3.310</td>
</tr>
<tr>
<td>OBSTRUCTED NASOLACRIMAL DUCT</td>
<td>3.320</td>
</tr>
<tr>
<td>ORAL CANDIDIASIS/MONILIASIS (THRUSH)</td>
<td>3.330</td>
</tr>
<tr>
<td>PEDICULOSIS CAPITIS (HEAD LICE)</td>
<td>3.340</td>
</tr>
<tr>
<td>PERIODICITY SCHEDULE - INFANCY-ADOLESCENCE</td>
<td>3.350</td>
</tr>
<tr>
<td>Periodicity Schedule - 22 years &amp; over RESCINDED NOV 2014</td>
<td>3.360</td>
</tr>
<tr>
<td>PITYRIASIS ROSEA</td>
<td>3.370</td>
</tr>
</tbody>
</table>
POISON IVY DERMATITIS ...................................................................................... 3.380
PREVENTION OF VITAMIN DEFICIENCY - PRENATAL ................................. 3.390
SARCOPTES SCABIEI (SCABIES) ........................................................................ 3.400
SEBORRHEIC DERMATITIS (CRADLE CAP) ....................................................... 3.410
SMOKING CESSATION ............................................................................................ 3.420

Smoking Cessation Counseling & Treatment
Patient Willing to Make Quit Attempt
Patient Not Willing to Make Quit Attempt
Pharmacotherapies for Smoking Cessation
Patient Tobacco Survey
Tobacco Cessation Clinical Form - Initial Clinical Visit
Tobacco Cessation Clinical Form - Resupply Visit

TINEA CORPORIS (RINGWORM) ........................................................................... 3.430
TINEA CRURIS (JOCK ITCH, GYM ITCH) ............................................................ 3.440
TINEA VERSICOLOR ............................................................................................... 3.450
TESTING FOR TB INFECTION (TST OR IGRA) .................................................... 3.460
TUBERCULIN SKIN TESTING, TWO STEP PROCEDURE ............................... 3.470
TUBERCULOSIS, CASE OR SUSPECT (INITIAL VISIT) ........................................ 3.480
TUBERCULOSIS, LATENT TUBERCULOSIS INFECTION (LTBI) ......................... 3.490
Urine Abnormal, Adult RESCINDED NOV 2012 3.500
Urine Abnormal, Child RESCINDED NOV 2012 3.510
URTICARIA (HIVES) ................................................................................................ 3.520
VARICELLA (CHICKENPOX) .................................................................................. 3.530

SECTION IV: IMMUNIZATIONS

COMVAX (Combined HIB/Hep B) ............................................................................. 4.010
DIPHTHERIA, TETANUS TOXOID & ACELLULAR PERTUSSIS (DTaP) .......... 4.020
DIPHTHERIA and TETANUS TOXOID, PEDIATRIC (DT Pediatric) ............... 4.030
DIPHTHERIA, TETANUS TOXOID, ACELLULAR PERTUSSIS,
INACTIVATED POLIO VACCINE (DTaP-IPV) (Kinrix) ................................. 4.040
DIPHTHERIA, TETANUS TOXOID and ACELLULAR PERTUSSIS,
INACTIVATED POLIO, HAEMOPHILUS INFLUENZAE TYPE B
COMBINATION VACCINE (DTaP-IPV-Hib)(Pentacel)................................. 4.050
GENERIC INJECTIONS......................................................................................... 4.060
HAEMOPHILUS b CONJUGATE VACCINE (Hib) ............................................. 4.070
HEPATITIS A VACCINE....................................................................................... 4.080
HEPATITIS A INACTIVATED, HEPATITIS B RECOMBINANT VACCINE
ADULT (age 18 years and up)(Twinrix)................................................................. 4.090
HEPATITIS B RECOMBINANT VACCINE, Pre-Exposure (Birth - 18 years) .... 4.100
HEPATITIS B RECOMBINANT VACCINE, Pre-Exposure Adult (19 years & Up) 4.110
HERPES ZOSTER (SHINGLES) VACCINE - LIVE VACCINE ......................... 4.115
HUMAN PAPILLOMAVIRUS VACCINE (HPV) ................................................. 4.120
H1N1 Influenza RESCINDED MAY 2014............................................................ 4.125
H1N1 (LAIV) RESCINDED MAY 2014................................................................ 4.126
INFLUENZA VACCINE, LIVE ATTENUATED (LAIV) ........................................ 4.130
INFLUENZA VACCINE, TRIVALENT INACTIVATED (TIV) .................................................. 4.140
MEASLES, MUMPS, RUBELLA VACCINE (MMR) .................................................. 4.150
MENINGOCOCCAL B CONJUGATE ........................................................................... 4.151
MENINGOCOCCAL VACCINE (MENACTRA) ......................................................... 4.160
MENINGOCOCCAL VACCINE (MENOMUNE) ......................................................... 4.170
PEDIARIX (D TaP/HEP B/IPV) .............................................................................. 4.180
PNEUMOCOCCAL VACCINE FOR CHILDREN AGES 6 WEEKS THROUGH 18 YEARS ........................................................................................................... 4.190
PNEUMOCOCCAL VACCINE FOR ADULTS WITH HIGH RISK CONDITIONS AGES 19 THROUGH 64 YEARS ........................................................................ 4.191
PNEUMOCOCCAL VACCINE FOR ADULTS ≥65 YEARS ......................................... 4.200
POLIO VACCINE, INACTIVATED ........................................................................ 4.210
RABIES VACCINE, POST-EXPOSURE .................................................................. 4.220
RABIES VACCINE, PRE-EXPOSURE ................................................................... 4.230
ROTAVIRUS VACCINE ......................................................................................... 4.240
TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) (7 through 18 years, Adacel or Boostrix) .......................................................... 4.250
TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) (19 years and up, Adacel or Boostrix) ............................................................. 4.260
TETANUS AND DIPHTHERIA TOXOID, ADULT TYPE (Td) ................................. 4.270
TETANUS PROPHYLAXIS IN WOUND MANAGEMENT ........................................ 4.280
VARICELLA VACCINE .......................................................................................... 4.290

SECTION V: SEXUALLY TRANSMITTED DISEASES

CHLAMYDIA AND GONORRHEA, CASE OR CONTACT ......................................... 5.010
CHLAMYDIA TRACHOMATIS, PARTNER DELIVERED THERAPY .......................... 5.030
Gonorrhea, Case or Contact, COMBINED WITH CHLAMYDIA 5.010 ................. 5.040
HEPATITIS B, CASE OR PRESUMPTIVE ............................................................... 5.060
HEPATITIS B, INFANT CONTACTS ........................................................................ 5.070
HEPATITIS B, ALL OTHER CONTACTS ............................................................... 5.080
HEPATITIS C, (NON - A, NON - B), CASE .......................................................... 5.090
HERPES SIMPLEX (GENITAL HERPES) .............................................................. 5.100
HIV TESTING AND COUNSELING ................................................................. 5.110
PEDICULOSIS PUBIS (PUBIC LICE) ................................................................. 5.130
SYphilis, CASE OR CONTACT ........................................................................... 5.140
TRICHOMONIASIS, CASE OR CONTACT ............................................................. 5.160

SECTION VI: DISASTER PREPAREDNESS AND BIOTERRORISM

ANTHRAX VACCINE .......................................................................................... 6.010
POTASSIUM IODIDE ADMINISTRATION ............................................................. 6.020
SMALLPOX VACCINE ......................................................................................... 6.030

APPENDICES
A. ADDITIONAL IMMUNIZATION INFORMATION ........................................... 7.010
5 Rights of medication administration
Vaccines & Routes of Administration
How to Administer Intramuscular (im) Injections
How to Administer Subcutaneous (sc) Injections
Emergency Supplies and Equipment
Pharmacy Policy 3.03B, Labeling of Medications

TIPS ON SAFEGUARDING YOUR VACCINE SUPPLY
(Refer to Vaccine Storage and Handling Toolkit)

B. LIST OF STANDARD ABBREVIATIONS ................................................. 7.020

INDEX........................................................................................................ 7.040
SUSPECTED OPIOID OVERDOSE

Background Information
Naloxone is a proven tool in the battle against drug abuse and overdose death. Overdose death can occur when too much of an opioid medication is taken resulting in a dangerously low respiratory rate. Naloxone is an opioid antagonist reversing the effects of the drug including respiratory depression and sedation by competing with the opiate receptors in the CNS. Naloxone ONLY works if a person has opioids in their system; it is not effective against respiratory depression due to non-opioid drugs. Naloxone does not produce tolerance to the opioid antagonist effect or physical dependence.

SUBJECTIVE
History of:
- Known or suspected opioid use
- Report by family or friends of recent opioid use
- Unknown patient history should not prevent medical management of suspected opioid overdose

Symptoms:
- Loss of consciousness
- Choking sounds, or a snore-like gurgling noise
- Body is very limp
- Face is very pale or clammy
- Fingernails and lips turn blue or purplish black

OBJECTIVE
- Unresponsive to outside stimulus
- Breathing is very slow and shallow, erratic, or has stopped
  (The best predictor of opioid poisoning is a respiratory rate <12)
- Pulse (heartbeat) is slow, erratic, or not there at all
- Pinpoint pupils

ASSESSMENT
- Possible opioid overdose

PLAN
- Attempt to awake with sternal rub
- Activate emergency response system
- Perform rescue breathing if necessary
Dosing for adults and children weighing ≥ 8 pounds

- Administer naloxone 0.4mg/mL 1cc INTRAMUSCULARLY in the deltoid or anterolateral thigh (always administer in the anterolateral thigh if <1 year old)
- If there is no response or inadequate response (respiratory rate remains below 12 breaths per minute AND patient is still unresponsive) after 2 – 3 minutes, administer a second Naloxone 0.4 mg IM dose.

Dosing for children weighing < 8 lbs

Administer initial Naloxone dose of 0.1 mg/kg IM in the anterolateral thigh muscle

<table>
<thead>
<tr>
<th>Infant weight</th>
<th>Naloxone Dose</th>
<th>Amount to administer based on 0.4 g/ml Naloxone stock vial</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-8 lbs</td>
<td>0.3 mg</td>
<td>0.75 ml</td>
</tr>
<tr>
<td>4-5 lbs</td>
<td>0.2 mg</td>
<td>0.5 ml</td>
</tr>
<tr>
<td>&lt; 3 lbs</td>
<td>0.1 mg</td>
<td>0.25 ml</td>
</tr>
</tbody>
</table>

The goal of naloxone administration is NOT a normal level of consciousness, but adequate ventilation.

- If desired response is not achieved, repeat dosing every 2 to 3 minutes as needed until emergency medical assistance arrives or until Naloxone supply is depleted
- If normal breathing resumes, place in rescue position and administer oxygen
- Remain with patient until EMS arrives
- If not breathing adequately, resume rescue breathing
- Naloxone will wear off within 1-2 hours so encourage patient to go to ER

There are no medical contraindications to administering Naloxone to prevent opioid overdose death. This includes administering to pregnant women.

Precautions

Administration of naloxone may precipitate symptoms of acute withdrawal which may include pain, tachycardia, hypertension, fever, sweating, abdominal cramps, diarrhea, nausea, vomiting, AGITATION, AND IRRITABILITY. This typically occurs with IV administration due to the rapid onset of action.

REFERENCES

Coffin, P., Prevention of Lethal Opioid Overdose in the Community. In: UpToDate, Saxon, AJ (Ed), UpToDate, Waltham, MA, 2016


Stolbach, A., Hoffman, R., Acute Opioid Intoxication in Adults. In: UpToDate, Traub, S.(Ed), UpToDate, Waltham, MA 2016

TDH Naloxone webpage http://tn.gov/health/topic/information-for-naloxone

Yin, S., Opioid Intoxication in Children and Adolescents. In: UpToDate, Burns, M., (Ed), UpToDate, Waltham, MA 2016
Community Located Vaccination Clinics

The Emergency Protocols below for Anaphylaxis and Syncope are to be used during community located vaccination clinics

ANAPHYLAXIS

SUBJECTIVE

History of:
- Recent injection, often within minutes
- Previous allergic reaction

Symptoms may include:
- Headache
- Anxiety/feeling of impending doom
- Difficult breathing/tightness in throat and chest, wheezing
- Feeling faint
- Localized or generalized pruritus
- Swelling of hands, feet, face and tongue

OBJECTIVE

- Weak, irregular, and rapid pulse (above 100 beats per minute)
- Rapid and shallow respirations
- Fall in blood pressure
- Patient apprehensive and perspiring heavily, may be confused
- Lips, tongue, and eyelids are frequently swollen
- Hives, rash, erythema
- Cyanosis of the lips and nail beds
- Labored breathing and wheezing (wheezes are heard throughout chest)
- Nasal discharge, nasal congestion, change in voice quality, sensation of throat closure or choking, shortness of breath

ASSESSMENT

Anaphylactic reaction

PLAN

There are NO absolute contraindications to epinephrine use in anaphylaxis:

- Initiate emergency response system
- Place patient in supine position
- Assure adequate airway - administer CPR if indicated
- Question regarding most recent weight
Administer aqueous epinephrine 1:1000 INTRAMUSCULAR according to Emergency Drug Chart A
May repeat epinephrine dosage every 5-15 minutes, if necessary

EMERGENCY DRUG CHART

Aqueous Epinephrine (Adrenaline) = 0.01 ml./kg. IM

**Epinephrine Dose**

Recommended dose is 0.01 mg/kg body weight up to 0.5 mg maximum dose.
May be repeated every 5–15 minutes for a total of 3 doses.

<table>
<thead>
<tr>
<th>Age group</th>
<th>Range of weight (kg)*</th>
<th>Range of weight (lb)</th>
<th>1 mg/mL injectable (1:1000 dilution); INTRAMUSCULAR Minimum dose: 0.05 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1–6 months</td>
<td>4–8.5 kg</td>
<td>9–19 lb</td>
<td>0.05 mL (or mg)</td>
</tr>
<tr>
<td>7–36 months</td>
<td>9–14.5 kg</td>
<td>20–32 lb</td>
<td>0.1 mL (or mg)</td>
</tr>
<tr>
<td>37–59 months</td>
<td>15–17.5 kg</td>
<td>33–39 lb</td>
<td>0.15 mL (or mg)</td>
</tr>
<tr>
<td>5–7 years</td>
<td>18–25.5 kg</td>
<td>40–56 lb</td>
<td>0.2–0.25 mL (or mg)</td>
</tr>
<tr>
<td>8–10 years</td>
<td>26–34.5 kg</td>
<td>57–76 lb</td>
<td>0.25–0.3 mL (or mg)</td>
</tr>
<tr>
<td>11–12 years</td>
<td>35–45 kg</td>
<td>77–99 lb</td>
<td>0.35–0.4 mL (or mg)</td>
</tr>
<tr>
<td>13 years &amp; older</td>
<td>46+ kg</td>
<td>100+ lb</td>
<td>0.5 mL (or mg) – max.</td>
</tr>
</tbody>
</table>

**NOTE:** Dosing by weight is preferred. If weight is not known or not readily available, dosing by age is appropriate.

SYNCOPE/VASOVAGAL REACTION/COMMON FAINT

SUBJECTIVE

**Symptoms may include:**
- Nausea
- Lightheadedness
- Roaring in ears sensation
- Dimming vision

**History to establish cause:**
Gather as much information as possible from patient, family/friend(s), or bystanders
- What was the person doing prior to the injection?
- What were the prodromal symptoms (i.e., nausea, lightheadedness etc.)?
- Are there any predisposing factors (i.e., age, chronic disease, fasting?)
- Are there any precipitating factors (i.e., a painful or fearful procedure)?
- What did others witness?
- Were there any signs of seizure?

**OBJECTIVE**

Diaphoresis  
Loss of color (pale/ashen)  
Loss of consciousness and postural tone

**ASSESSMENT**

Syncope – Possible Vasovagal Reaction

**PLAN**

Assure airway, breathing, and circulation  
Remove any inciting stimuli (stress, pain, fear, etc.)  
Elevate legs, loosen tight clothing such as a tie or belt  
Monitor vital signs  
When there is immediate recovery, review history and refer patients with any significant findings to a primary care provider  
Initiate emergency response (call EMT/911) if recovery is not complete within minutes  
Continue to check vital signs, assure airway, breathing, and circulation until EMT arrives  
Give report to EMT team

**REFERENCES**

Community Health Services Policy #3.4A


Simons, F., MD, FRCPC. Anaphylaxis: Rapid Recognition and Treatment. In: UpToDate, Feldweg, A., (Ed), UpToDate, Waltham, MA, 2016
CERVICAL CANCER SCREENING
PROCEDURE

The Tennessee Department of Health has several programs such as Family Planning, Breast and Cervical Cancer Screening and Women’s Health that offer cervical cancer screening beginning at age 21.

Clients should be prepared for cervical cancer screening by being given the following information prior to the day of pap smear:

- Avoid douching for 2 days before the examination
- Avoid putting ANYTHING into the vagina for 2 days before the exam (optimal)
- Make appointment for Pap test 1-2 weeks after the end of menses (optimal)
- Whenever possible, have abnormal vaginal secretions treated before a Pap test is scheduled

SUBJECTIVE
The client reports to a program or service within the health department that could include cervical cancer screening.

OBJECTIVE
The client meets the screening criteria established according to ASCCP (American Society for Colposcopy and Cervical Pathology) guidelines.

ASSESSMENT
The client is appropriate for cervical cancer screening. The timing of her screening test is based upon her age and/or history and/or the results of her last Pap test.

PLAN
- Review the Pap history in the chart.
- Based on history, prepare the necessary materials for a Pap test. If a pap test is not done, document reason in the chart.
- Explain to the client how she will receive her Pap results. Provide Reproductive Health Teaching (see below).
- Schedule for next appointment
- Complete follow-up for the Pap results as directed. (see written order of provider and Family Planning Guidelines)

HEALTH TEACHING

- Explain that nearly all sexually active individuals will be exposed to HPV sometime in their lifetime; 80% by age 50. Most women will have a natural immune response and clear the HPV on their own. Only a few at risk individuals will eventually develop cervical cancer from HPV exposure. This process takes many years. Therefore, cervical cancer screening must continue throughout a woman’s life.
- Assess client’s current immunization status including HPV vaccine. Offer vaccine(s) based on current vaccine guidelines.
- Provide an overview of all sexually transmitted infections.
• Promote and instruct in the correct use of condoms.
• Review the risks associated with the following high-risk sexual behaviors:
  ➢ Unprotected intercourse, including oral and anal sex
  ➢ Early onset of sexual intercourse (i.e., first sexual intercourse before the age of 18) including increased likelihood of exposure to STDs and the increased risk of teen pregnancy and unintended pregnancy. Both teen pregnancy and unintended pregnancy are associated with infant mortality and morbidity.
  ➢ Multiple sexual partners.
  ➢ Having a sexual partner who has multiple partners.
  ➢ Numerous sexual partners in a lifetime (serial monogamy).
• Review the increased risk of cervical cancer in women who smoke cigarettes.
• Review the risk to daughters of women who took the hormone diethylstilbestrol (DES) during their pregnancies (for clients born before 1970, DES was used primarily to prevent repeat miscarriages). These daughters are at greater risk for developing vaginal and cervical cancers.

FAMILY PLANNING GUIDELINES GENERAL INFORMATION

How Do We Screen For Cervical Cancer?

The Tennessee Department of Health screens women for cervical cancer using liquid-based cytology (Pap) testing. A benefit of liquid-based testing is to allow for triage of atypical squamous cells of undetermined significance (ASCUS) for presence of HPV without having to bring the client back in to collect another sample.

What is HPV Testing?

Human papilloma virus (HPV) testing refers to the identification of high–risk (oncogenic) HPV strains that can become precursors to cervical cancer. HPV testing is a tool used to determine the need for a colposcopy in women with atypical squamous cells, undetermined significance (ASC-US) results and is referred to as reflex testing. HPV testing is also used in women aged 30-65 as an adjunct to cytology for cervical cancer screening to lengthen the screening interval (if both test are negative); this is referred to as co-testing.

Indications for HPV testing include the following:
• Reflex testing – to determine the need for colposcopy in women with ASC-US cytology result.
• Co-testing – use as an adjunct to cytology for cervical cancer screening in women aged 30 years and older.

Who and When Do We Screen For Cervical Cancer?

Cervical cancer screenings should begin at 21 years old. While a pap test may not be necessary at all Family Planning Program visits, an annual physical exam including but not limited to breast exam and pelvic (visual and bimanual) exam is still recommended. Counsel regarding the importance of preventative services including pap testing.
Summary of Cervical Cancer Screening Guidelines

<table>
<thead>
<tr>
<th>Population</th>
<th>Recommended Screening Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age under 21</td>
<td>Do not screen</td>
</tr>
<tr>
<td>Age 21-29</td>
<td>Cytology (Pap smear) every 3 years. Reflex HPV for pap result of ASCUS</td>
</tr>
<tr>
<td>Age 30-64</td>
<td>Cytology every 3 years with reflex HPV for ASCUS results or Co-testing (cytology &amp; HPV) every 5 years</td>
</tr>
<tr>
<td></td>
<td>Note: Clients must be offered both options and allowed to choose based on their preference.</td>
</tr>
<tr>
<td>Age 65 and up</td>
<td>Discontinue screening if, since age 55, patient has had 2 consecutive negative HPV tests or 3 consecutive negative cytology results</td>
</tr>
<tr>
<td>Hysterectomy with removal of cervix</td>
<td>Screening indicated ONLY for women with a history of either: 1) CIN2+ in the past 20 years, or 2) a history of cervical cancer ever.</td>
</tr>
<tr>
<td>Vaccinated against HPV</td>
<td>Follow age-specific recommendations (same as unvaccinated women)</td>
</tr>
</tbody>
</table>

Please note these guidelines do not apply to the following high-risk populations:
- HIV positive: CDC recommends that women with HIV have cervical cytology screening twice in the first year after diagnosis and annually thereafter. Screening should be initiated at the age when diagnosed with HIV even if younger than 21 years old.
- Immunosuppressed: ACOG recommends annual cytology screening starting at age 21, No recommendation exist from the ASCCP.
- Exposure to diethylstilbestrol (DES) in utero: No recommendation exists from ACOG or ASCCP
- Previous treatment for CIN2 or higher: Continue routine age-based screening for 20 years after the initial post treatment surveillance period, even if screening continues past age 65.

Refer to the following algorithms from American Society for Colposcopy and Cervical Pathology (ASCCP). Full details of these guidelines may be reviewed at ASCCP’s
Unsatisfactory Cytology

- HPV unknown (any age)
- HPV negative (age ≥ 30)
- HPV positive (age ≥30)

Repeat Cytology after 2-4 months

- Abnormal
  - Manage per ASCCP Guideline

- Negative
  - Routine screening (HPV-/unknown) or Cotesting @ 1 year (HPV+)

- Unsatisfactory
  - Colposcopy
Cytology Negative for Intraepithelial Lesion or Malignancy (NILM) but Endocervical/Transformation (EC/TZ) Absent/Insufficient

Ages 21-29

- Routine screening

Age ≥30

- HPV negative
  - HPV testing (Preferred)
- HPV unknown
  - Repeat cytology in 3 years (Acceptable)

HPV positive

- Cytology + HPV test in 1 year
- *HPV DNA Genotyping

Manage per ASCCP Guideline

*Family Planning and Breast and Cervical Screening Programs do not currently pay for HPV DNA Genotyping.
Management of Women ≥ Age 30, who are Cytology Negative, but HPV Positive

- **Repeat Cotesting** @ 1 year Acceptable
- **≥ ASC or HPV Positive**
  - Cytology Negative and HPV Negative
    - Repeat Cotesting @ 3 years
  - ≥ ASC or HPV Positive
    - Repeat Cotesting @ 3 years
- **HPV 16 or 18 Positive**
  - *HPV DNA Genotyping* Acceptable
  - Manage per ASCCP Guideline
- **HPV 16 or 18 Negative**
  - Repeat Cotesting @ 1 year
  - Manage per ASCCP Guideline

*Family Planning and Breast and Cervical Screening Programs do not currently pay for HPV DNA Genotyping.*
Management of Women > 25 years with Atypical Squamous Cells of Undetermined Significance (ASC-US) on Cytology
(For women between 21-24 years, see following algorithm.)

Repeat Cytology
@ 1 year
Acceptable

HPV Testing
Preferred

≥ ASC
HPV Positive
(Managed the same as women with LSIL)

HPV Negative
Repeat Cotesting
@ 3 years

Negative
Routine Screening

Colposcopy
Endocervical sampling preferred in women with no lesions, and those with inadequate colposcopy; it is acceptable for others

Manage per ASCCP Guideline
Management of Women Ages 21-24 years with either Atypical Squamous Cells of Undetermined Significance (ASC-US) or Low-grade Squamous Intraepithelial Lesion (LSIL)

Women ages 21-24 years with ASC-US or LSIL

- Repeat Cytology @ 12 months Preferred
- HPV Positive
  - Negative, ASC-US, or LSIL
  - Repeat Cytology @ 12 months
  - Negative X 2
    - Routine Screening
  - ≥ ASC
    - Colposcopy
- HPV Negative
  - Reflex HPV Testing Acceptable for ASC-US only
    - HPV Negative
      - Routine Screening

Routine Screening
Management of Women >25 years with Low-grade Squamous Intraepithelial Lesions (LSIL)
(For women between 21-24 years, see previous algorithm.)

*After colposcopy, management is directed by the colposcopist. Refer to the ASCCP algorithm booklet April 2013 for further guidelines.
Initial Workup of Women with Atypical Glandular Cells (AGC)

After colposcopy, management is directed by the colposcopist. Refer to the ASCCP algorithm booklet April 2013 for further guidelines.

*Includes unexplained vaginal bleeding or conditions suggesting chronic anovulation.
Management of Women with Atypical Squamous Cells:
Cannot Exclude High-grade SIL (ASC-H)
(For women between 21-24 years, see following algorithm.)

Colposcopy
Regardless of HPV status

No CIN2, 3
Manage per ASCCP Guideline

CIN2, 3
Manage per ASCCP Guideline
Management of Women Ages 21-24 years with Atypical Squamous Cells, Cannot Rule Out High-grade SIL (ASC-H) and High-grade Squamous Intraepithelial Lesion

Colposcopy
Immediate loop electrosurgical excision is unacceptable

No CIN2, 3

CIN2, 3

Observation with colposcopy & cytology*
@ 6 month intervals for up to 2 years

Two Consecutive Cytology Negative Results and No High-grade Colposcopic Abnormality

Routine Screening

Manage per ASCCP Guideline

Other results

HSIL Persists for 24 months with no CIN2, 3 identified

Biopsy

CIN2, 3
(If no CIN2, 3, continue observation)

Manage per ASCCP Guideline for young women with CIN2, 3

*If colposcopy is adequate and endocervical sampling is negative. Otherwise a diagnostic excisional procedure is indicated.

+Not if client is pregnant.
Management of Women with High-grade Squamous Intraepithelial Lesions (HSIL)

**Immediate Loop Electrosurgical Excision**  
(Not if patient is pregnant or ages 21-24)

**Colposcopy**  
(with endocervical assessment)

- No CIN2, 3
- CIN2, 3

Manage per ASCCP Guideline

*Management options may vary if the woman is pregnant, postmenopausal, or ages 21-24.*
REFERENCES


CERUMEN, IMPACTED
(EAR WAX)

SUBJECTIVE
Ear feels plugged
Diminished hearing
Itching may be present
History is negative for:
  Ear drainage
  Perforation of ear drum(s) Ear pain
  Ear surgery, e.g., “tubes”

OBJECTIVE
Hardened and packed cerumen
Tympanic membrane not visible

ASSESSMENT
Impacted cerumen

PLAN
Hearing assessment according to age
Recommend softening ear wax with the following warmed to body temperature:
Use glycerin or mineral oil to fill each ear canal two or three times a day for 7 days or
recommend filling ear canal with Debrox daily for 3-4 days.

Parent or guardian should be instructed in proper manipulation of ear lobe and cartilage
to facilitate drops flowing into the ear
Discourage the use of anything smaller than the finger tip for cleaning the ear canal,
(i.e., Q-tips, bobby pins, toothpicks, match sticks, twigs or straw)

Referral Indicators:
Earaches, ear pain
Ear drainage
Perforation of tympanic membrane
Impacted cerumen that fails to respond to above management
Impaired hearing or delayed and/or impaired speech
Children less than 2 years of age
Febrile

Follow-Up:
Follow up as needed

Reference:
http://www.webmd.com/a-to-z-guides/ear-wax
CONSTIPATION, ACUTE, CHILD

SUBJECTIVE
- Malaise, abdominal cramping
- History of hard, dry, stools
- Possible history of involuntary fecal soiling in a previously toilet trained or older child
- History of infrequent passage of stools relative to the individual's usual habit
- Pain and/or straining at defecation; reluctance to sit on toilet
- Stool streaked with blood
- Diet and medication history

OBJECTIVE
- Signs of dehydration
- Anal fissure or evidence of irritation
- Abdominal distention with or without palpable firm mass
- Stool streaked with bright blood
- Visible hemorrhoid

ASSESSMENT
- Acute childhood constipation

PLAN
- Encourage defecation when urge presents
- Adjust diet to allow for adequate fluid and carbohydrate intake
- For infants 1 month and older: 1 ounce a day for every month of life up to about 4 months (a 3-month-old baby would get 3 ounces) of apple or pear juice; or use 1 to 2 tablespoons per day of dark corn syrup
- Once your infant is taking solids you can try vegetables and fruits, especially prunes.
- Older infants - increase fluid intake; increase amounts of pureed fruits in the diet, especially prunes and plums; the amount needed will vary with individual infants
- Older children - Increase fluid intake; add prunes, apricots, and figs to the daily diet; include high-residue substances such as bran, whole wheat, oatmeal, and green leafy vegetables in daily diet
- If these dietary changes don’t help, call the PCP
- Discourage use of suppositories, laxatives, or enemas unless specifically ordered by health department physician or APN.
- For minor anal irritation, advise warm sitz baths and use of petroleum jelly or ointment and/or hypoallergenic moist wipes
- For previously toilet trained child, support for feet when toileting

NOTE: DO NOT GIVE HONEY TO CHILDREN LESS THAN ONE YEAR OLD DUE TO DANGER OF BOTULISM
Referral Indicators:
- Persistent, severe, or recurrent abdominal pain
- Persistent fecal soiling
- Persistent constipation
- Vomiting, dehydration, fever
- Breakdown of skin around anus
- Blood streaked stool

Follow-Up:
Patient/parent will be asked to contact health provider if not resolved in 24-48 hours

Reference
Mayo Clinic, Guide To Self-Care, Fifth Edition 2006
DIAPER DERMATITIS (DIAPER RASH)

SUBJECTIVE
Caretaker reports diaper rash
Irritability

OBJECTIVE
Contact or irritant dermatitis: Chafed, reddened, non-raised areas over genital and buttocks area
Infected dermatitis: Inflamed, bright red, indurated and tender skin; With satellite lesions; thick white plaques with an erythematous base may be present on oral mucus membrane (thrush), especially during or following antibiotic therapy (see oral candidiasis/moniliasis)

ASSESSMENT
Contact or Infected Diaper Dermatitis

PLAN
For Contact Diaper Dermatitis:
• Change diaper as soon as possible after it becomes wet or soiled;
• Clean diaper area with warm water and a hypoallergenic/or unscented soap after each bowel movement; dry gently but thoroughly after each diaper change
• Leave diaper off during nap time to allow drying of the area
• A layer of protective diaper ointment/cream or a corn starch based powder may be applied to skin with each diaper change.
• Do not overdress infant
• Discourage use of waterproof pants, plastic covered diapers, tightly pinned or double diapers, scented diapers, and scented diaper wipes as many contain perfume or alcohol
• DO NOT USE TALCUM POWDER, BAKING SODA, OIL, OR PETROLEUM JELLY
• Provide laundry instructions for cloth diapers, if applicable:
  Suggest laundering diapers in mild hypoallergenic detergent and rinse thoroughly
  Use only hypoallergenic fabric softener

Referral Indicators:
Infected diaper dermatitis
Suspicion of burn
No response to treatment within 2-3 days
Presence of systemic involvement (e.g., fever)

Follow up:
Parent will be asked to contact health provider in 24-48 hours if not improved

Reference:
Mayo Clinic, Guide To Self-Care, Fifth Edition 2006
American Academy of Pediatrics, Healthy Children
http://www.healthychildren.org/English/ages-stages/baby/diapers-clothing/Pages/Diaper-Rash-Solution.aspx
FLUORIDE DEFICIENCY

NOTE:

- The use of dietary fluoride supplements is one alternative means of providing fluoride protection to the teeth of children 6 months old to 16 years of age who consume fluoride-deficient water with 0.6 ppm fluoride or less.

- Dietary fluoride supplements, in the form of daily tablets, lozenges, liquids, or vitamin-fluoride combinations, provide systemic benefits to developing teeth as well as topical benefits to erupted teeth. When practical, supplements should be prescribed as chewable tablets or lozenges to maximize the topical effects of fluoride.

- When prescribed and used appropriately, fluoride supplements provide benefits similar to those obtained from ingesting optimally-fluoridated water over the same period of time.

- When improperly prescribed, fluoride supplements may cause mild enamel fluorosis (white spots on teeth). Therefore, systemic fluoride supplements should never be prescribed to children in fluoridated communities who are already receiving optimally fluoridated water (0.7 ppm fluoride).

- Because of an increase in the milder forms of dental fluorosis associated with fluoride ingestion in excess of that necessary to prevent tooth decay, a conservative approach to fluoride supplementation should be used and in accordance with the recently revised guidelines.

- If a child’s primary drinking water source is a well, spring, or non-fluoridated community water system, a water sample must first be taken and analyzed to determine its fluoride content and what dosage of fluoride supplement, if any, is needed.

SUBJECTIVE

- No other systemic source of fluoride besides that present in foods and beverages processed with fluoridated water
- Request for dietary fluoride supplement
- Age 6 months to 16 years

OBJECTIVE

- Private community water supply with a fluoride content 0.6 ppm fluoride or below as confirmed by fluoride assay
- Dental caries are more common in areas of fluoride deficient water supply.
ASSessment
Fluoride Deficiency

Plan
Drinking water should be analyzed for fluoride content prior to supplementation in order to determine if supplements are necessary and how much to prescribe.

To determine the level of fluoride in the child’s existing water supply:
1. Obtain water sample bottles from either Fluoridation Specialist (TDEC Nashville Env. Field Office, Division of Water Supply, 711 R.S. Gass Blvd, Nashville, TN 37216, Telephone 615-687-7037 or the Regional Dental Director.
2. Provide parent or guardian with 1 water sample bottle, request slip for fluoride determination.
3. Instruct patient on the correct procedure for collecting and handling of the water sample:
   a. Using a kitchen or bathroom faucet allow cold water to run for at least 30 seconds.
   b. Rinse out the sample bottle twice before filling.
   c. Fill sample bottle with cold water and screw on cap firmly.
   d. Mail the sample within 3 days.

Estimate an effective fluoride concentration as indicated (child is consuming water from multiple sources)

Example: If the home water supply is tested and the fluoride concentration is 0.2 ppm, but it only accounts for half of the child’s daily water intake (0.2 ppm x 0.50 = 0.1 ppm) and the daycare water supply has a known fluoride concentration of 1.0 ppm and it accounts for the remaining half of the child’s daily intake (1.0 ppm x 0.50 ppm) a dietary fluoride supplement (if prescribed) should be based on the effective fluoride concentration of 0.6 ppm and not 0.2 Ppm

Issue fluoride supplements according to the following dosage schedule:

Dietary Supplemental Fluoride Dosage Schedule in mg F/day
Revised, ADA Winter 1994

<table>
<thead>
<tr>
<th>Age of Child</th>
<th>ppm fluoride in water supply</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0-0.3 ppm</td>
</tr>
<tr>
<td>Birth to 6 mo</td>
<td>0</td>
</tr>
<tr>
<td>6 mo to 3 yrs</td>
<td>0.25 mg</td>
</tr>
<tr>
<td>3 to 6 yrs</td>
<td>0.5mg</td>
</tr>
<tr>
<td>6-16 yrs</td>
<td>1.0mg</td>
</tr>
</tbody>
</table>

Issue on a “one bottle at a time” basis
Each bottle should not exceed the recommended limit of 120 mgs of fluoride
**Health Teaching:**
There is a well-documented decline in dental caries in children in the United States which is due to widespread use of various forms of fluoride.

Even people living in communities where water supplies are not fluoridated still benefit from exposure to fluorides found in toothpaste, mouth rinses, professionally applied fluorides and in foods processed in cities where water supplies are fluoridated (i.e., the “halo” phenomenon).

In order to reduce risk of dental fluorosis, it is recommended that parents closely supervise tooth brushing by young children to prevent their ingestion of fluoride toothpaste and to ensure that only very small quantities (pea-sized amounts) are used.

Careful use of fluoride is particularly appropriate during the time of anterior tooth enamel development (birth to 8 years).

**Follow-Up:**
The parent or guardian of the child will be asked to return for a refill when one bottle is near completion or if the fluoride status of the water supply changes.

**Reference**
MMWR August 17, 2001 / 50 (RR14) 1-42

MMWR “Achievements….etc.” October 22, 1999 / 48 (41); 933-940

### Recommendations for Preventive Pediatric Health Care

**Bright Futures/American Academy of Pediatrics**

These guidelines represent a consensus by the American Academy of Pediatrics (AAP) and Bright Futures. The AAP continues to emphasize the great importance of continuity of care in communities and supporting the AAP's recommendations to reduce fragmentation of care.

Refer to the specific guidance by age as listed in Bright Futures guidelines (Hagan JF, Shaw JS, Duncan PM, eds. Bright Futures Guidelines for Health Supervision of Infants, Children, and Adolescents. 3 ed. Elk Grove Village, Ill: American Academy of Pediatrics; 2008).

The recommendations in this statement do not indicate an exclusive course of treatment or standard of medical care. Variations, taking into account individual circumstances, may be appropriate.


No part of this statement may be reproduced in any form or by any means without prior written permission from the American Academy of Pediatrics. except for one copy for personal use.

---

### EARLY CHILDHOOD

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Breastfeeding</th>
<th>Carbohydrates</th>
<th>Dental Health</th>
<th>Immunization</th>
<th>Lead Screening</th>
<th>Tuberculosis Testing</th>
<th>Dyslexia Screening</th>
<th>Scoliosis Screening</th>
<th>Vision Screening</th>
<th>Hearing Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>9-36 months</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

### MIDDLE CHILDHOOD

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Breastfeeding</th>
<th>Carbohydrates</th>
<th>Dental Health</th>
<th>Immunization</th>
<th>Lead Screening</th>
<th>Tuberculosis Testing</th>
<th>Dyslexia Screening</th>
<th>Scoliosis Screening</th>
<th>Vision Screening</th>
<th>Hearing Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-5 years</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

### ADOLESCENCE

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Breastfeeding</th>
<th>Carbohydrates</th>
<th>Dental Health</th>
<th>Immunization</th>
<th>Lead Screening</th>
<th>Tuberculosis Testing</th>
<th>Dyslexia Screening</th>
<th>Scoliosis Screening</th>
<th>Vision Screening</th>
<th>Hearing Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>12-18 years</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

---

1. If a child comes under care for the first time at any point in the schedule, or if any items are not accomplished at the suggested age, the schedule should be brought up-to-date at the earliest possible opportunity.

2. A prenatal visit is recommended for parents who are at high risk for fetal death, for foster parents, and for those who request such services. The prenatal visit should include anticipatory guidance, medically appropriate history, and a discussion of breastfeeding and planned method of feeding, by the health provider.

3. Every infant should have a newborn examination after birth, and breastfeeding should be encouraged (and instruction and support should be offered).

4. Every infant should have a postnatal visit within 2-4 hours after discharge from the hospital to review evaluation for feeding and lactation. Breastfeeding infants should receive normal breast-feeding, exclusive breastfeeding, and mothers should receive encouragement and instruction, as recommended in the AAP’s “Screening, Counseling, and Referral of Infants and Young Children in Primary Care Settings” guidelines.

5. If primary water source is deficient in fluoride, varnish may be applied and fluoride varnish may be used to improve dental health.

---

**Key**

- **A**: To be performed
- **R**: Risk assessment to be performed with appropriate action to follow, if positive
- **C**: No range during which a service may be provided

---

**References**


Summary of changes made to the Bright Futures/AAP Recommendations for Preventive Pediatric Health Care
(Periodicity Schedule)

This Schedule reflects changes approved in October 2015 and published in January 2016. For updates, visit www.aap.org/periodicityschedule.

Changes made October 2015

- Vision Screening: The routine screening at age 18 has been changed to a risk assessment.
- Footnote 7 has been updated to read, "A visual acuity screen is recommended at ages 4 and 5 years, as well as in cooperative 3 year olds. Instrument based screening may be used to assess risk at ages 12 and 24 months, in addition to the well visits at 3 through 5 years of age. See 2016 AAP statement, "Visual System Assessment in Infants, Children, and Young Adults by Pediatricians (http://pediatrics.aappublications.org/content/137/1/1.51) and "Procedures for Evaluation of the Visual System by Pediatricians" (http://pediatrics.aappublications.org/content/137/1/1.52)."

Changes made May 2015

- Oral Health: A subheading has been added for fluoride varnish, with a recommendation from 6 months through 5 years.
- Footnote 25 wording has been edited and also includes reference to the 2014 clinical report, "Fluoride Use in Caries Prevention in the Primary Care Setting" (http://pediatrics.aappublications.org/content/134/3/626) and 2014 policy statement, "Maintaining and Improving the Oral Health of Young Children" (http://pediatrics.aappublications.org/content/134/6/1224.full).
- Footnote 26 has been added to the new fluoride varnish subheading: See USPSTF recommendations (http://www.uspreventiveservicestaskforce.org/uspstf/uspsdnch.htm). Once teeth are present, fluoride varnish may be applied to all children every 3-6 months in the primary care or dental office. Indications for fluoride use are noted in the 2014 AAP clinical report "Fluoride Use in Caries Prevention in the Primary Care Setting" (http://pediatrics.aappublications.org/content/134/3/626).

Changes made March 2014

Changes to Developmental/Behavioral Assessment

- Alcohol and Drug Use Assessment: Information regarding a recommended screening tool (CRAFFT) was added.
- Depression: Screening for depression at ages 11 through 21 has been added, along with suggested screening tools.

Changes to Procedures

- Dyslipidemia screening: An additional screening between 9 and 11 years of age has been added. The reference has been updated to the AAP-endorsed National Heart Blood and Lung Institute policy (http://www.nhlbi.nih.gov/guidelines/cvd_ped/index.htm).
- Hematocrit or hemoglobin: A risk assessment has been added at 15 and 30 months. The reference has been updated to the current AAP policy (http://pediatrics.aappublications.org/content/126/5/1040.full).
- STI/HIV screening: A screen for HIV has been added between 16 and 18 years. Information on screening adolescents for HIV has been added in the footnotes. STI screening now references recommendations made in the AAP Red Book. This category was previously titled "STI Screening."
- Cervical dysplasia: Adolescents should no longer be routinely screened for cervical dysplasia until age 21. Indications for pelvic exams prior to age 21 are noted in the 2010 AAP statement "Gynecologic Examination for Adolescents in the Pediatric Office Setting" (http://pediatrics.aappublications.org/content/126/3/583.full).
- Critical Congenital Heart Disease: Screening for critical congenital heart disease using pulse oximetry should be performed in newborns, after 24 hours of age, before discharge from the hospital, per the 2011 AAP statement, "Endorsement of Health and Human Services Recommendation for Pulse Oximetry Screening for Critical Congenital Heart Disease" (http://pediatrics.aappublications.org/content/128/1/190.full).

See www.aap.org/periodicityschedule for additional updates made to footnotes and references in March 2014.
ROTAVIRUS VACCINE
(RotaTeq® “RV5” by Merck, Rotarix® “RV1” by GSK)

GENERAL INFORMATION

Rotavirus causes severe diarrhea and is usually accompanied by fever and vomiting. It is the most common cause of severe gastroenteritis in infants and young children in the U.S. Rotavirus is seasonal, with peak numbers of cases occurring in the winter and early spring. Before the introduction of vaccine in 2006, rotavirus diarrhea resulted in about 200,000 emergency room visits and 55,000 hospitalizations in the US annually. Transmission occurs through the fecal-oral route.

Rotavirus vaccines are live vaccines administered by mouth, between the age of 6 weeks zero days and 8 months zero days of age. They may be administered simultaneously with other vaccines. Two rotavirus vaccines are licensed in the U.S.: Rotateq® by Merck (abbreviated “RV5” by CDC) and Rotarix® by GSK (abbreviated “RV1” by CDC). RV5(Rotateq) is a three-dose series and RV1 (Rotarix) is a two-dose series: the ACIP/CDC expresses no preference between the two vaccines. Please note: this protocol follows ACIP/CDC recommendations for a harmonized schedule of the two brands, which differs from product package inserts.

Special situations:
Infants in contact with pregnant women or persons with compromised immune systems may be vaccinated.

Infants who have received or will receive blood or antibody-containing products may receive the vaccine at any time. Previously, it was recommended that such infants wait 42 days before vaccination.

Re-administration of a dose to an infant who spits up or vomits during or after administration of the vaccine is not generally recommended. If this occurs, continue series at normal interval.

If any dose in the series is RV5, or if the brand of any dose is unknown, a total of 3 doses must be administered to complete the series. Although preferable to use one brand for the entire series, vaccination should not be deferred because the product previously used is unknown or unavailable.
### 3-Dose Immunization Schedule: If any dose is Rotateq® (RV5) or unknown brand

<table>
<thead>
<tr>
<th>Dose</th>
<th>Product</th>
<th>Recommended age</th>
<th>Minimum interval to next dose</th>
<th>Special Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>RotaTeq (RV5) or Rotarix (RV1)</td>
<td>2 months: Administer between age 6 weeks and 14 weeks 6 days (42-104 days)</td>
<td>4 weeks</td>
<td>If dose 1 was given at ≥15 weeks, the series may be continued</td>
</tr>
<tr>
<td>Dose 2</td>
<td>RotaTeq (RV5) or Rotarix (RV1)</td>
<td>4 months</td>
<td>4 weeks</td>
<td></td>
</tr>
<tr>
<td>Dose 3 Final dose</td>
<td>RotaTeq (RV5) or Rotarix (RV1)</td>
<td>6 months</td>
<td></td>
<td>Do not administer after age 8 months 0 days</td>
</tr>
</tbody>
</table>

### 2-Dose Immunization Schedule: If Using Rotarix® (RV1) Only

<table>
<thead>
<tr>
<th>Dose Number</th>
<th>Recommended age at administration</th>
<th>Minimum interval to next dose</th>
<th>Special Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>2 months: Administer between age 6 weeks and 14 weeks 6 days (42-104 days)</td>
<td>4 weeks</td>
<td>If dose 1 was given at ≥15 weeks, the series should be completed</td>
</tr>
<tr>
<td>Dose 2 Final dose</td>
<td>4 months</td>
<td></td>
<td>Do not administer after 8 months 0 days of age.</td>
</tr>
</tbody>
</table>

**Contraindications** to giving the vaccine include the following:
- Infants <6 weeks (42 days) or >8 months 0 days (precise age in days not specified)
- Infants with a history of severe allergic reaction to a prior dose of rotavirus vaccine or to any rotavirus vaccine component
- Infants with a severe (anaphylactic) reaction to latex should not receive Rotarix (RV1). RotaTeq (RV5) should be used because it is latex free.
- Previous history of intussusception
- Infants diagnosed with Severe Combined Immunodeficiency (SCID). Screening for SCID was added to Tennessee’s Newborn Screening Program effective January 1, 2016.
Precautions (risks and benefits of vaccination should be carefully evaluated under the following circumstances):

- Moderate to severe acute illness (defer until illness resolves) [Note: Low grade fever <100.5°F or mild upper respiratory infections are not reasons for deferring]
- Preexisting chronic gastrointestinal disease (e.g., chronic diarrhea, congenital abdominal disorders)
- Altered immunocompetence including:
  - Blood disorders or cancers involving the bone marrow or lymph system
  - Infants on high dose systemic corticosteroids
  - Infants with an immunodeficiency other than SCID

Adverse Reactions:
Severe allergic reaction to vaccine (rare)
High fever

PLAN
- Ask parent/guardian about contraindications, precautions
- Have parent/guardian read Vaccine Information Statement
- If using Rotarix (RV1), reconstitute vaccine according to manufacturer’s instructions
- Administer the vaccine by mouth according to the manufacturer instructions [if an incomplete dose is administered or the infant vomits, repeating the dose is not recommended]
- Counsel regarding side effects of vaccine
- Advise parent/guardian to return for the next dose in a minimum of 4 weeks
- Advise to wait in clinic for 20 minutes after administration of vaccine
- Record manufacturer and lot number of the vaccine administered, date vaccine and VIS given, address of facility, and name and title of person administering vaccine
- Instruct patient/guardian to contact Health Department if adverse reaction occurs (complete VAERS)

Referral Indicators:
Infants with precautions to vaccination other than an acute moderate to severe illness should be referred for a health department physician order.

REFERENCES

RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent) Vaccine package insert, Merck, Revised September 2011.

Rotarix (Rotavirus Vaccine, Live Attenuated) Vaccine package insert, GSK, Revised February 2011.


INDEX

-A-
Abbreviations, 7.020
Acne, 3.010
Acute Asthma Attack, 1.010
Acute Poisoning, 1.020
Acute Upper Respiratory Infection (Common Cold), 3.020
Administering Vaccines: Dose, Route, Site, and Needle Size, 7.010
All Methods, Quick Start, 2.010
Anaphylaxis, 1.030
Anemia, Iron Deficiency, 3.025
Animal Bites, 1.040
Anthrax Vaccine, 6.010
Apgar Scoring System, 1.070
Ascariasis (Roundworms), 3.030

-B-
Basic Infertility Services, 2.011
Blood Pressure, Elevated, Adult, 3.040
Blood Pressure, Elevated, Child, 3.050
Burn, First Degree, 1.050

-C-
Cardiac Emergencies, 1.060
Cerumen Impacted (Ear Wax), 3.060
Cervical Cancer Screening, 2.020
Chickenpox, 3.530
Chiggers (Dematophilis Pentrans), 3.070
Chlamydia Trachomatis and Gonorrhea, Case or Contact, 5.010
Chlamydia Trachomatis, Contact Partner Delivered Therapy, 5.030
Cholesterol Risk Assessment, 3.090
Combined Hormonal Contraception, 2.030
Common Cold, 3.020
Common Faint, 1.150
Cradle Cap in Infants, 3.410

-D-
Dematophilis Pentrans (Chiggers), 3.070
Diaper Dermatitis (Diaper Rash), 3.120
Diaphragm, 2.060
Diarrhea, 3.130
Dilation for Retinal Imaging, 3.135
Diphtheria, Tetanus Toxoid and Acellular Pertussis Vaccine (DTaP), 4.020
Diphtheria and Tetanus Toxoid, Pediatric Vaccine (DT), 4.030
Diphtheria, Tetanus Toxoid, Acellular Pertussis, Inactivated Polio Vaccine (DTaP-IPV) (Kinrix), 4.040
Diphtheria, Tetanus Toxoid, Acellular Pertussis, Inactivated Polio, Haemophilus Influenzae Type B Combination Vaccine (DTaP-IPV-Hib) (Pentacel), 4.050
ascarasis (Roundworms), 3.030

-E-
Ear Wax, removal, 3.060
Emergency Childbirth, 1.070
Emergency Contraceptive Pills (ECPs), 2.080
Emergency Drug Chart, 1.030
Enterobius Vermicularis (Pinworms), 3.140

-F-
Family Planning Reference Section 2.170
Fertility Awareness-Based Methods (FAM), 2.090

Comvax Vaccine (Hib/Hep B), 4.010
Condoms, Sponge and Spermicidal Agents, 2.040
Constipation, Acute, Child, 3.100
Constipation, Adult, 3.110
Contraceptive Patch, see Quick Start
Fever Blister, 3.230
Five Rights of Medication Administration, 7.010
Fluoride Deficiency, 3.160
Fluoride Varnish, 3.170
Folic Acid Prophylactic Therapy for Women Aged 10-44, 3.180
Foodborne Outbreak Investigation, 3.190

-G-
Generic Injections, 4.060
Genital Herpes, 5.100
Gingivostomatitis, 3.240
Gonorrhea, Case or Contact, 5.040

-H-
Haemophilus b Conjugate Vaccine (Hib), 4.070
Haemophilus Influenza, Invasive Type B, Contact, 3.200
Head Lice, 3.340
Heat Rash, 3.310
Hemorrhage/Hemorrhagic Shock, 1.080
Hepatitis A, Case or Presumptive, 3.210
Hepatitis A, Post Exposure, 3.220
Hepatitis A Vaccine, 4.080
Hepatitis A Inactivated, Hepatitis B Recombinant Vaccine (Twinrix), 4.090
Hepatitis B, Case or Presumptive, 5.060
Hepatitis B, Infant Contact, 5.070
Hepatitis B, Other Non-Occupational Contacts, Post-Exposure, 5.080
Hepatitis B Recombinant Vaccine, Pre-exposure (Birth through 18 years), 4.100
Hepatitis B Recombinant Vaccine, Pre-exposure Adult (19 years and up), 4.110
Hepatitis C (Non-A, Non-B), Case, 5.090
Herpes Simplex - Type I (Fever Blister), 3.230
Herpes Simplex Type II (Genital Herpes), 5.100
Herpes Zoster Vaccine, 4.115

Herpetic Stomatitis, 3.240
Hives, 3.520
HIV Testing and Counseling, 5.110
Hordeolum (Sty), 3.250
How to Administer
Intramuscular (IM) Injections, 7.010
Subcutaneous (SC) Injections, 7.010
Human Papillomavirus (HPV) Vaccine, 4.120

-I-
Immune Globulin Hepatitis A Prophylaxis Dosage Chart, 3.220
Impetigo/Bullous Impetigo, 3.260
Influenza Vaccine, Live Attenuated (LAIV), 4.130
Influenza Vaccine, Trivalent Inactivated (TIV), 4.140
Insect Bites, 1.090
Intrauterine Contraceptive (IUC), 2.100

-J-
Jock Itch, Gym Itch, 3.440

-K-
Kinrix®, 4.040

-L-
Laceration, 1.100
Lead Toxicity Screening, 3.280
List of Standard Abbreviations, 7.020

-M-
Measles, Mumps, Rubella Vaccine (MMR), 4.150
Medication Administration, 7.010
Meningococcal Meningitis, Case, 3.290
Meningococcal Meningitis, Contact, 3.300
Meningococcal Conjugate Vaccine (Menactra), 4.160
Meningococcal Polysaccharide Vaccine (Menomune), 4.170
Miliaria, 3.310

-N-
Nasolacrimal Duct, Obstructed, 3.320

-O-
Obstructed Nasolacrimal Duct, 3.320
Oral Candidiasis/Moniliasis, 3.330

-P-
Pediarix (DTaP/Hep B/IPV), 4.180
Pediculosis Capitis, 3.340
Pediculosis Pubis, 5.130
Pentacel (DTaP/IPV, Hib), 4.050
Periodicity Schedule (Infancy-Adolescence), 3.350
Pinworms, 3.140
Pityriasis Rosea, 3.370
Pneumococcal Vaccine, Children 6 wks through 18 years, 4.190
Pneumococcal Vaccine for adults with high risk conditions age 19-64, 4.191
Pneumococcal Vaccine adults ≥ 65 years old, 4.200
Poison Ivy Dermatitis, 3.380
Poisoning, Acute, 1.020
Poison Oak, 3.380
Poison Sumac, 3.380
Polio Vaccine, Inactivated (IPV), 4.210
Potassium Iodide (KI) Administration, 6.020
Preconception Health Services, 2.105
Pregnancy Test, 2.110
Prevention of Vitamin Deficiency - Prenatal, 3.390
Preventive Health Care, Children, 3.350
Prickly Heat, 3.310
Progestin-only Implants, 2.120
Progestin-only Injectable Contraception, 2.130
Progestin Only Pills (Minipill), 2.140
Pubic Lice, 5.130
Puncture Wound, 1.110

-Q-

-R-
Rabies Vaccine, Post-Exposure, 4.220
Rabies Vaccine, Pre-Exposure, 4.230
Respiratory Emergency, 1.120
Ringworm, 3.430
Rotavirus Vaccine, 4.240
Roundworms, 3.030

-S-
Sarcoptes Scabiei, 3.400
Scabies, 3.400
Seborrheic Dermatitis, 3.410
Seizures, 1.130
Shingles Vaccine, 4.115
Shock, 1.140
Smallpox Vaccine (Vaccinia), 6.030
Smoking Cessation, 3.420
Sterilization, 2.150
Sty, 3.250
Suspected Opioid Overdose, 1.145
Syncope/Vasovagal Reaction/Common Faint, 1.150
Syphilis, Case or Contact, 5.140

-T-
Tetanus, Diphtheria and Acellular Pertussis Vaccine (Tdap) (7 through 18 years), 4.250
Tetanus, Diphtheria and Acellular Pertussis Vaccine (Tdap) (19 through 64 years), 4.260
Tetanus and Diphtheria Toxoid, Adult Type (Td), 4.270
Tetanus Prophylaxis in Wound Management, 4.280
Thrush, 3.330
Tick Bite, 1.160
Tinea Corporis (Ringworm), 3.430
Tinea Cruris, (Jock Itch), 3.440
Tinea Versicolor, 3.450
Tobacco Cessation, 3.420
Trichomoniasis, Case or Contact, 5.160
Testing for TB Infection, 3.460
Tuberculosis, Case or Suspect, (Initial Visit) 3.480
Tuberculosis, Initial Visit, 3.480
Tuberculosis, Treatment of Latent TB Infection, 3.490
Tuberculin Skin Testing, Two Step Procedure, 3.470
Twinrix (Adult Hep A, Hep B), 4.090

Upper Respiratory Infection, Acute, 3.020
Urticaria, 3.520

Vaccine Adverse Event Reporting System (VAERS), 7.010
Vaccine Clinic, Community Located, 1.170
Vaccines and Route of Administration, 7.010
Varicella, 3.530
Varicella Vaccine, 4.290
Vasovagal Reaction, 1.150
Vaginal Contraceptive Ring, see Quick Start

Wound, Puncture, 1.110